Copertina

Atypical population pharmacokinetics of hydromethylthionine in patients with Alzheimer's disease explains unexpected phase 3 trial results

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Eline van Maanen, Antonio Gonçalves, Lu Chen, Floris Fauchet, Sinziana Cristea, James Smith, Tom Baddeley, Helen Shiells, Fiona Hewitt, Bjoern O. Schelter, Claude M. Wischik
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2026
Soggetti:	British Journal of Clinical Pharmacology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

The feasibility of pharmacokinetic‐based dosing of hydroxyurea for children with sickle cell anaemia in Uganda: Baseline results of the alternative dosing and prevention of transfusions trial
di: Alexandra Power‐Hays, et al.
Pubblicazione: (2025)

Population pharmacokinetic/target engagement modelling of tozorakimab in healthy volunteers and patients with chronic obstructive pulmonary disease
di: Muhammad Waqas Sadiq, et al.
Pubblicazione: (2024)

Epidural methadone and morphine pharmacokinetics and clinical effects in healthy volunteers: A randomized, crossover‐design trial
di: Alexander Hincker, et al.
Pubblicazione: (2024)

A phase 1, randomized, crossover trial to assess the effect of itraconazole on the pharmacokinetics of dordaviprone in healthy adults
di: Shamia L. Faison, et al.
Pubblicazione: (2025)

Physiologically based pharmacokinetic modelling predicts altered maternal pharmacokinetics of amitriptyline during pregnancy
di: Maike Scherf‐Clavel, et al.
Pubblicazione: (2025)

Population pharmacokinetics of vancomycin in term neonates with perinatal asphyxia treated with therapeutic hypothermia
di: Marlotte A. A. van der Veer, et al.
Pubblicazione: (2024)

Clozapine and norclozapine pharmacokinetic interaction with pantoprazole
di: Orwa Albitar, et al.
Pubblicazione: (2026)

Physiologically based pharmacokinetic model for oxcarbazepine active metabolite to predict pharmacokinetics in paediatric patients with renal impairment and adjust dosages
di: Cheng‐jie Ke, et al.
Pubblicazione: (2025)

Development of a generalized pharmacokinetic model to characterize clinical pharmacokinetics of monomethyl auristatin E‐based antibody–drug conjugates
di: Hsuan‐Ping Chang, et al.
Pubblicazione: (2024)

Physiologically based pharmacokinetic modelling of cefoperazone in paediatrics
di: Qiushi Wang, et al.
Pubblicazione: (2024)

Randomised, phase 1 evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of iptacopan in healthy volunteers
di: Irina Baltcheva, et al.
Pubblicazione: (2026)

Pharmacokinetics of subcutaneous and intravenous bolus doses of morphine in palliative care cancer patients receiving infusion of morphine: A pharmacokinetic substudy of a randomized controlled trial
di: Eva Gravdahl, et al.
Pubblicazione: (2025)

C‐model: A comprehensive enhanced pharmacokinetic/pharmacodynamic simulation environment targeting the complement system
di: Lucía Alfonso‐González, et al.
Pubblicazione: (2025)

Clinical pharmacokinetics and pharmacodynamics of empagliflozin in patients with heart failure
di: Juliane Rascher, et al.
Pubblicazione: (2024)

Effect of fluconazole on the pharmacokinetics of ainuovirine in healthy adult subjects
Pubblicazione: (2024)

Silencing drug transporters in human primary muscle cells modulates atorvastatin pharmacokinetics: A pilot study
di: Emilia Hoste, et al.
Pubblicazione: (2025)

First‐in‐human safety, tolerability, pharmacokinetics and pilot food‐effect study of the candidate antimalarial compound MMV367
di: Andrea Kuemmerle, et al.
Pubblicazione: (2025)

JAK–STAT inhibitory effect of IN‐115314, a novel small molecule inhibitor, and pharmacokinetic/pharmacodynamic study in canine
di: Jae‐Hun Ahn, et al.
Pubblicazione: (2025)

Population pharmacokinetic analysis of doravirine in real‐world people with HIV
di: Paul Thoueille, et al.
Pubblicazione: (2024)

Population pharmacokinetics of levofloxacin in breastmilk in patients with rifampicin‐resistant tuberculosis
di: Sharon Sawe, et al.
Pubblicazione: (2025)

The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of mitiperstat
di: Chandrali S. Bhattacharya, et al.
Pubblicazione: (2024)

Population pharmacokinetics and optimized dosing of cefuroxime in critically ill patients
di: Jaap W. A. Mouton, et al.
Pubblicazione: (2025)

Minimal impact of pregnancy on rilpivirine pharmacokinetics: A POPPK approach
Pubblicazione: (2024)

A drug–drug interaction study and physiologically based pharmacokinetic modelling to assess the effect of an oral 5‐lipoxygenase activating protein inhibitor on the pharmacokinetics of oral midazolam
di: Jane Knöchel, et al.
Pubblicazione: (2024)

Translational modelling to predict human pharmacokinetics and pharmacodynamics of a Bruton's tyrosine kinase‐targeted protein degrader BGB‐16673
di: Yue Wu, et al.
Pubblicazione: (2024)

Lamivudine and tenofovir pharmacokinetic variability in people with HIV in Papua New Guinea
di: Natália Bordin Andriguetti, et al.
Pubblicazione: (2025)

Clinical study of the pharmacokinetics and pharmacodynamics of Xininurad tablets in patients with renal impairment
di: Xiaoni Wang, et al.
Pubblicazione: (2025)

Model based comparison of cabotegravir pharmacokinetics following thigh and gluteal injections
Pubblicazione: (2024)

Population pharmacokinetics of long‐term hydroxychloroquine therapy in patients with rheumatic diseases
di: Chunlan Yang, et al.
Pubblicazione: (2024)

Population pharmacokinetics and exposure–response relationships of dostarlimab in primary advanced or recurrent endometrial cancer in part 1 of RUBY
di: Mita Kuchimanchi, et al.
Pubblicazione: (2024)

Sex‐specific impact of repeated adolescent vapour exposure to JWH‐018 on dopamine response, behaviour and pharmacokinetics across adolescence and adulthood
di: Nicholas Pintori, et al.
Pubblicazione: (2025)

First‐in‐human assessment of safety and pharmacokinetics of EP9001A:an anti‐nerve growth factor antibody for chronic pain treatment
di: Yue Cheng, et al.
Pubblicazione: (2025)

Core medication use in general practice prescriptions: A pilot study evaluating the Drug Utilization 90% Index in Irish general practice
di: Caroline McCarthy, et al.
Pubblicazione: (2024)

Unravelling sources of variability on rocuronium pharmacokinetics: Implications for prolonged recovery in older patients
di: Miriam S. R. Happ, et al.
Pubblicazione: (2025)

Optimization of vigabatrin dosage in children with epileptic spasms: A population pharmacokinetic approach
di: Agathe Molimard, et al.
Pubblicazione: (2024)

Personalized parathyroid hormone therapy for hypoparathyroidism: Insights from pharmacokinetic‐pharmacodynamic modelling
di: Maira Visscher, et al.
Pubblicazione: (2024)

Population pharmacokinetics and dosing of dispersible moxifloxacin formulation in children with rifampicin‐resistant tuberculosis
di: Megan Palmer, et al.
Pubblicazione: (2025)

Use of population pharmacokinetic‐pharmacodynamic modelling to inform antimalarial dose optimization in infants
di: Clifford G. Banda, et al.
Pubblicazione: (2024)

Physiologically‐based pharmacokinetic modelling of long‐acting injectable cabotegravir and rilpivirine in pregnancy
di: Shakir Atoyebi, et al.
Pubblicazione: (2024)

Pregnancy‐related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosis
di: Paulette Magnas, et al.
Pubblicazione: (2026)